Meeting
2023 ASCO Annual Meeting
Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses.
Authors
Yan Moore
Omega Therapeutics, Cambridge, MA
Yan Moore , William Senapedis , Kayleigh Gallagher , Elmer Figueroa , Madison Pacaro , Defne Yarar , Eugine Lee , Thomas McCauley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4116)
DOI
10.1200/JCO.2023.41.16_suppl.4116
Abstract #
4116
Poster Bd #
437
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Investigation of predictive biomarkers in patients treated with atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802).
First Author: Hideaki Bando
Poster
2024 ASCO Annual Meeting
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.
First Author: Daneng Li
Poster
2024 ASCO Genitourinary Cancers Symposium
Comprehensive analysis of targetable alterations in urachal cancer by NGS.
First Author: David Joseph Benjamin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Artificial intelligence (AI)-powered tumor microenvironment (TME) analysis to identify potential biomarkers for ICIs with or without bevacizumab in hepatocellular carcinoma (HCC).
First Author: Hong Jae Chon